ATXI

Avenue Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website avenuetx.com
Employees(FY) 2
ISIN US05360L4032

Performance

-10.12%

1W

-62.18%

1M

-65.89%

3M

-74.56%

6M

-69.11%

YTD

-95.4%

1Y

Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

Advanced Technical Analysis

Technical Analysis of ATXI 2024-05-10

Overview:

In analyzing the technical indicators for ATXI over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key indicators, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysi...

See more ...

Recent News & Updates

2024-05-15 20:30
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)(Globenewswire)
2024-05-15 09:55
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-14 20:30
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-04-28 20:00
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds(Globenewswire)
2024-04-23 19:30
Avenue Therapeutics Announces Reverse Stock Split(Globenewswire)
2024-03-24 20:30
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024(Globenewswire)
2024-03-18 18:53
ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-18 04:05
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-03-14 20:15
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq(Globenewswire)
2024-03-10 20:00
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting(Globenewswire)
2024-02-21 19:30
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy(Globenewswire)
2024-01-15 19:40
Sidoti Events, LLC's Virtual January Micro-Cap Conference(Yahoo Finance)
2024-01-10 19:00
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference(Globenewswire)
2024-01-04 20:15
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds(Globenewswire)
2024-01-03 19:30
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol(Globenewswire)
2024-01-01 19:30
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)(Globenewswire)
2023-11-30 19:30
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting(Globenewswire)
2023-11-28 19:05
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?(Investorplace)
2023-11-13 03:05
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights(Globenewswire)
2023-11-02 03:00
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering(Globenewswire)
2023-10-30 21:15
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering(Globenewswire)
2023-09-04 20:30
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-14 04:01
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights(Yahoo Finance)
2023-08-10 04:15
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights(Yahoo Finance)
2023-07-31 20:30
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study(Yahoo Finance)
2023-07-26 20:30
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)(Yahoo Finance)
2023-07-24 20:30
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol(Yahoo Finance)
2023-05-15 04:01
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights(Yahoo Finance)
2023-05-11 20:30
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights(Yahoo Finance)
2023-04-26 20:30
Avenue Therapeutics to Present at Aegis Capital Virtual Conference(Yahoo Finance)

Page 1 of 4

previousnext